SurgiQuest is a technology company.
SurgiQuest has raised $27.0M across 2 funding rounds.
SurgiQuest has raised $27.0M in total across 2 funding rounds.
SurgiQuest has raised $27.0M in total across 2 funding rounds.
SurgiQuest's investors include Aphelion Capital, Fifth Wall.
SurgiQuest is a medical technology company that develops and markets innovative access technologies for robotic and laparoscopic surgery, focusing on minimally invasive surgery (MIS) solutions like the proprietary AirSeal® System. This system features a valve-free trocar design that eliminates traditional seals and duckbill valves, enabling stable pneumoperitoneum, continuous smoke evacuation, and use of non-cylindrical instruments, while improving perioperative efficiency for surgeons and patient stability for anesthesia teams[1][2][3]. Incorporated in 2006 and headquartered in Connecticut, the company raised $92M before being acquired, serving hospitals and surgical teams performing procedures such as hysterectomies, addressing longstanding issues like scope smudging, seal failures, and insufflation instability in MIS[1][2].
SurgiQuest was founded in 2006 in Connecticut by executives with deep roots in surgical innovation, many hailing from United States Surgical Corporation, a pioneer in stapling and laparoscopy[1][3]. The idea emerged from frustration with conventional trocars plagued by circular seals and duckbill valves since the 1990s, which caused hassles like scope smudging, fragmented specimen removal, and seal disintegration. Early development pivoted to a revolutionary valve-free trocar, necessitating a new insufflation control unit for circulatory flow that maintained stable pneumoperitoneum and evacuated surgical smoke—unlocking benefits like fearless operation during challenging scenarios (e.g., colpotomy) and easier patient ventilation[1]. Pivotal traction came post-launch as surgeons adopted it for robotic and laparoscopic procedures, validating its transformative potential[1][3].
SurgiQuest rides the wave of expanding minimally invasive surgery (MIS), driven by demand for robotic-assisted procedures that reduce recovery times and complications amid aging populations and rising surgical volumes. Its timing capitalized on post-2000s laparoscopy maturation, addressing unmet needs in pneumoperitoneum stability amid growing robotic adoption (e.g., hysterectomy, general surgery)[1][2]. Market forces like FDA-cleared innovations and competition from peers (e.g., Advanced Surgical Concepts' single-incision devices) favor its circulatory flow tech, influencing the ecosystem by enabling complex MIS without traditional limitations and inspiring ancillary tools for smoke management and instrument versatility[1][2][3].
Post-acquisition, SurgiQuest's AirSeal® technology is poised for wider integration into robotic platforms, fueled by MIS growth and trends like AI-enhanced visualization and outpatient procedures. Evolving regulations and post-pandemic surgical backlogs will amplify demand for efficiency boosters like stable insufflation. Its influence may expand through acquirer scaling, shaping standards for valve-free access and patient-centric MIS—echoing its founding vision that future surgery demands past-rejecting tech[1][2].
SurgiQuest has raised $27.0M across 2 funding rounds. Most recently, it raised $8.0M Series D in December 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2012 | $8.0M Series D | Aphelion Capital, Fifth Wall | |
| Jul 1, 2011 | $19.0M Series C | Aphelion Capital, Fifth Wall |